Correlation between interleukin-4 and advanced fibrosis in chronic hepatitis C patients
- VernacularTitle:Элэгний С вирүсийн шалтгаант архаг үрэвсэлтэй өвчтөнд цусны интерлейкин-4 түвшин нэмэгдэх нь фиброз улам даамжирч байгааг илтгэх нь
- Author:
Serjbayar G
1
;
Bolor U
1
;
Chia-Yen D
2
;
Batbold B
1
Author Information
1. Institute of Medical Sciences named after Shagdarsuren T.
2. Kaohsiung Medical University, Taiwan
- Publication Type:Journal Article
- Keywords:
HCV;
Liver fibrosis;
Cytokines;
Interleukin 4;
Liver fibrosis indexes
- From:Mongolian Medical Sciences
2021;197(3):26-32
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:Various cytokine dynamics has been associated with chronic hepatitis C virus (HCV)
infection. We hypothesized that cytokines have an important role in fibrosis development in HCV
infection.
Methods:All patients received liver biopsies to validate the severity of chronic hepatitis when enrolled
in this study. Fluorescent Bead immunoassay was used to measure the following serum cytokine
levels: Interferon γ, tumor necrosis factor α, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and
IL-12. Various statistical analyses were used as appropriate.
Results:From all the liver biopsy proven 92 HCV-infected patients, 49 (53.3%) were male, 23 (25%)
patients had advanced (fibrosis grades 3-4) fibrosis, and the mean age of the study population was
51.9 ± 9.4 years. Elevation of baseline IL-4 level (>490 pg/mL) was associated with liver fibrosis grade
by X2 test (odds ratio [OR] = 2.99; 95%, CI = 1.02-8.78; p = 0.042) and multivariate logistic regression
(OR = 4.26; 95% CI = 1.13-16.02; p = 0.032). Also, IL-4 had strong diagnostic value in advanced liver
fibrosis by using area under receiver operating characteristics curve analysis. Assessment of fibrosis
score was consequently developed from our findings and compared with other noninvasive serum
markers to assess liver fibrosis.
Conclusion:This study provides evidence that increased IL-4 expression predicted advanced liver
fibrosis in treatment of HCV-infected patients.
- Full text:2021-197(3)-26-32.pdf
